Human MAGED2 ELISA Kit (V2LY-0626-LY4878)

Go to compare Compare Online Inquiry
Tested Data
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
0.0098 ng/mL
Detection Range
0.02-4.5 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
65.0 kDa
Components
  • Pre-coated ELISA plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
melanoma antigen family D, 2
Function
Regulates the expression, localization to the plasma membrane and function of the sodium chloride cotransporters SLC12A1 and SLC12A3, two key components of salt reabsorption in the distal renal tubule.
Biological Process
Female pregnancyManual Assertion Based On ExperimentIMP:UniProtKB
Negative regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIBA:GO_Central
Renal sodium ion absorptionManual Assertion Based On ExperimentIMP:UniProtKB
Cellular Location
Cytosol
Extracellular region
Membrane
Nucleolus
Nucleoplasm
Nucleus
Platelet alpha granule lumen
Involvement in disease
Bartter syndrome 5, antenatal, transient (BARTS5):
An X-linked recessive form of Bartter syndrome, a disorder characterized by impaired salt reabsorption in the thick ascending loop of Henle with pronounced salt wasting, hypokalemic metabolic alkalosis, and varying degrees of hypercalciuria. BARTS5 is an antenatal form beginning in utero with marked fetal polyuria that leads to polyhydramnios and premature delivery. It is characterized by severe but transient symptoms that can resolve with age.

Walsh, C. J., Micke, K., Elfman, H., Bock, M., Harper, T., Zaretsky, M., ... & Putra, M. (2023). Successful antenatal treatment of MAGED2‐related Bartter syndrome and review of treatment options and efficacy. Prenatal Diagnosis.

Shi, X., Liu, C., Zheng, W., Cao, X., Li, W., Zhang, D., ... & Chen, Y. (2023). Proteomic analysis revealed the potential role of MAGE-D2 in the therapeutic targeting of triple-negative breast cancer. Molecular & Cellular Proteomics, 100703.

Ju, X., Wang, Z., Wang, P., Ren, W., Yu, Y., Yu, Y., ... & Ding, Q. (2023). SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense. Mbio, 14(4), e01373-23.

Seaayfan, E., Nasrah, S., Quell, L., Kleim, M., Weber, S., Meyer, H., ... & Kömhoff, M. (2022). MAGED2 is required under hypoxia for cAMP signaling by inhibiting MDM2-dependent endocytosis of G-Alpha-S. Cells, 11(16), 2546.

Seaayfan, E., Nasrah, S., Quell, L., Radi, A., Kleim, M., Schermuly, R. T., ... & Kömhoff, M. (2022). Reciprocal Regulation of MAGED2 and HIF-1α Augments Their Expression under Hypoxia: Role of cAMP and PKA Type II. Cells, 11(21), 3424.

Reusch, B., Bartram, M. P., Dafinger, C., Palacio-Escat, N., Wenzel, A., Fenton, R. A., ... & Rinschen, M. M. (2022). MAGED2 controls vasopressin-induced aquaporin-2 expression in collecting duct cells. Journal of proteomics, 252, 104424.

Wu, X., Huang, L., Luo, C., Liu, Y., & Niu, J. (2021). A case report and literature review of a novel mutation in the MAGED2 gene of a patient with severe transient polyhydramnios. Frontiers in Pediatrics, 9, 778814.

Ma, M., Zhang, M., Zhou, Y., Yao, F., Wei, M., Li, Z., & Qiu, Z. (2021). A novel MAGED2 variant in a Chinese preterm newborn with transient antenatal Bartter’s syndrome with 4 years follow-up. BMC nephrology, 22(1), 1-4.

Mansor, S., Kuick, C. H., Lim-Tan, S. K., Leong, M. Y., Lim, T. Y. K., & Chang, K. T. E. (2020). 28. Novel fusion MAGED2-PLAG1 in endometrial stromal sarcoma. Pathology, 52, S142-S143.

Valino-Rivas, L., Cuarental, L., Agustin, M., Husi, H., Cannata-Ortiz, P., Sanz, A. B., ... & Sanchez-Niño, M. D. (2019). MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. Nephrology Dialysis Transplantation, 34(9), 1498-1507.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human MAGED2 ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.